Expression and Functionality of Bitter Taste Receptors in Ovarian and Prostate Cancer
Authors: Dupre Denis J. , Martin Louis , Nachtigal Mark 
Published: November 2023

Plants secondary metabolites often are poisonous to protect themselves against predators. The composition of ingested food is sensed by specialized sensory cells located in taste buds in the oral cavity, capable of detecting one of the basic taste qualities (sweet, sour, salty, umami, bitter, and possibly fat). In particular, bitter taste is detected in humans by 25 members of the bitter taste receptor (TAS2R) subfamily of G protein‐coupled receptors (GPCRs). Since plant poisonous metabolites are often bitter, sensing bitterness provides protection against poison consumption.Surprisingly, Tas2Rs are expressed in several extra‐oral tissues. For example, a role for extra‐orally expressed TAS2Rs was shown in airway bronchodilation, where TAS2Rs were expressed in various cell types lining the airways, and their stimulation with bitter drugs caused potent muscle relaxation; suggesting that inhaled bitter compounds could be used therapeutically for treatment of airway diseases. Recently, it was shown that mammary epithelial cells express Tas2Rs, and that the expression of some Tas2Rs is downregulated in breast cancer cells. Few studies have shown expression of Tas2Rs in cancer, and our preliminary results show expression and functionality of Tas2Rs in ovarian and prostate cancer, while it was previously reported for pancreatic and breast cancer. While extra‐oral expression of Tas2Rs was demonstrated in some tissues, their expression in diseases like cancer is poorly characterized. We analyzed data from online cancer databases for genetic alterations and noticed that Tas2R gene amplification was very high in breast and ovarian cancer, while few mutations or deletions were present, when compared to other cancers like prostate cancer. Interestingly, drug resistance in cancer cells is often linked to amplification of genes that change absorption of chemotherapeutic agent by cells. Bitter drugs like noscapine, a ligand for Tas2R14, sensitizes chemoresistant ovarian cancer cells to paclitaxel. It is possible that Tas2Rs could have an important role in the development of new therapeutic strategies, alone or in combination with current drug therapies.After showing the expression of Tas2R subtypes expressed in ovarian cancer samples, we would now like to analyze the signaling pathways activated by these receptors. Our preliminary work shows that Tas2Rs are functional and signal in cancer cells with an effect on apoptosis signaling, among others. Further characterization will be needed to understand the role of these receptors in cancer. Overall, the results from our work demonstrate the expression and functionality of Tas2Rs in cancer, and will help define a subset of Tas2Rs that could potentially be targeted for therapy with bitter drugs.Support or Funding InformationOperating funds from Beatrice Hunter Cancer Research Institute, Natural Sciences and Engineering Research Council of Canada (NSERC), and studentships from Canadian Institutes of Health Research and the Cancer Research Training Program of the Beatrice Hunter Cancer Research Institute, with funds provided by Motorcycle Ride for Dad – Nova Scotia Chapters.